Findings

What do systematic reviews say?

873 questions · 883 findings · 38 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 319 · 36.1%GRADE not reported 18 · 2%Very low 198 · 22.4%Low 186 · 21.1%Moderate 147 · 16.6%High 15 · 1.7%

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

Eradication of bacterial infection · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

Clinical improvement(visual analogue scale) · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

Pulmonary exacerbations · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

All‐cause mortality · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

The review found no eligible studies for this question.

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Survival · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
High

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 599 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: relative change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 578 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Treatment time (min) · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Quality of life · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Serum deposition Cmax · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Adverse events · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

FEV1 · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Participant satisfaction or preference · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD

Treatment time · adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD

Quality of life · adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found